1. Home
  2. KNSA vs SHC Comparison

KNSA vs SHC Comparison

Compare KNSA & SHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

N/A

Current Price

$79.55

Market Cap

4.9B

Sector

Health Care

ML Signal

N/A

Logo Sotera Health Company

SHC

Sotera Health Company

N/A

Current Price

$18.10

Market Cap

5.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KNSA
SHC
Founded
2015
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.2B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KNSA
SHC
Price
$79.55
$18.10
Analyst Decision
Strong Buy
Buy
Analyst Count
8
10
Target Price
★ $98.00
$22.72
AVG Volume (30 Days)
408.7K
★ 1.7M
Earning Date
10-27-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 225.00
68.75
EPS
0.27
★ 0.28
Revenue
$677,564,000.00
★ $1,163,617,000.00
Revenue This Year
$46.66
$7.16
Revenue Next Year
$22.90
$5.94
P/E Ratio
$291.67
★ $63.68
Revenue Growth
★ 60.09
5.74
52 Week Low
$35.53
$13.09
52 Week High
$82.94
$19.85

Technical Indicators

Market Signals
Indicator
KNSA
SHC
Relative Strength Index (RSI) 60.46 44.08
Support Level $73.81 $16.74
Resistance Level $81.42 $19.75
Average True Range (ATR) 2.60 0.49
MACD 0.30 -0.06
Stochastic Oscillator 86.28 39.46

Price Performance

Historical Comparison
KNSA
SHC

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

About SHC Sotera Health Company

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.

Share on Social Networks: